Dina M. Gifkins
Research Subjects
Dina M. Gifkins has a total of 44 co-authors. Here are the top co-authors by number of shared publications:
Alexander Marshall
Janssen Global Services, LLC, Raritan, NJ
2 shared publicationsJessica Fowler
Janssen Scientific Affairs, LLC, Horsham, PA
2 shared publications- Laura L. Hester
Janssen Research and Development Raritan New Jersey USA
2 shared publications Nina Kim
Janssen Scientific Affairs, LLC, Horsham, PA
2 shared publicationsAditi Shah
Analysis Group, Inc. Montréal Québec Canada
1 shared publicationAlexis A. Krumme
Global Epidemiology, Janssen Research and Development LLC Titusville New Jersey USA
1 shared publication
Latest Publications
- 8 August 2025
- Published by Wiley in Pharmacoepidemiology and Drug Safety
- Vol. 34 (8) , e70189
Review of Mother–Infant Linkage Algorithms in Health Care Data Sources
Introduction: Studies that use health care data to assess infant outcomes following maternal medication use in pregnancy require linkage of maternal and infant records. While such linkage is increasing among established and emerging data sources, linkage methods are heterogeneous and have not been thoroughly reviewed or evaluated to inform fitness for use. The objective of this study was to describe methods used to link maternal and infant records in health care databases for pharmacoepidemiology research.Methods: Multiple Medline searches were conducted using structured terms and known mother–infant linked data sources. Reference sections of identified key papers were also reviewed. From each publication, we abstracted information on the type(s) of data sources, data fields used for the linkage, linkage methodology, and any results of record linkage evaluation.Results: We reviewed 114 publications describing mother–infant linkages published from 1990 to 2025 that used data from North and South America, Europe, Asia, and Oceania. Linkage methods using administrative claims data only primarily relied on family ID and estimated dates of maternal delivery and infant birth; proportions of mothers linked with infants were 56%–90%. Use of vital records, such as birth certificates, alongside claims data resulted in higher linkage proportions (> 86% of deliveries); examples were identified in Taiwan, Europe, and several US states. Utilization of birth records together with hospital discharge data resulted in linkages of over 90% of deliveries. Linkages involving additional data types, such as electronic health records, were identified in Europe and the US. Mother–infant linkages were straightforward in regions with national birth registers that include identifiers for mother and infant, such as the Nordic countries, and within integrated delivery networks in the US that provide both health insurance and care. Although most mother–infant linkages used deterministic methods, probabilistic methods typically achieved greater linkage proportions while requiring more data fields. Validations were uncommon; two studies demonstrated high positive predictive value (> 95%) but lower sensitivity (20%–88%).Discussion: Successful mother–infant data linkage occurs throughout the world and is enabled by aligned health care and technology infrastructure and policy. To increase trust in evidence generated from linked data, we encourage researchers and journals to include a description of linking methods, a quantification of linkage success, and, when possible, an assessment of linkage validity in peer‐reviewed publications.
- 8 August 2025
- Published by Wiley in Pharmacoepidemiology and Drug Safety
- Vol. 34 (8) , e70189
Review of Mother–Infant Linkage Algorithms in Health Care Data Sources
Introduction: Studies that use health care data to assess infant outcomes following maternal medication use in pregnancy require linkage of maternal and infant records. While such linkage is increasing among established and emerging data sources, linkage methods are heterogeneous and have not been thoroughly reviewed or evaluated to inform fitness for use. The objective of this study was to describe methods used to link maternal and infant records in health care databases for pharmacoepidemiology research.Methods: Multiple Medline searches were conducted using structured terms and known mother–infant linked data sources. Reference sections of identified key papers were also reviewed. From each publication, we abstracted information on the type(s) of data sources, data fields used for the linkage, linkage methodology, and any results of record linkage evaluation.Results: We reviewed 114 publications describing mother–infant linkages published from 1990 to 2025 that used data from North and South America, Europe, Asia, and Oceania. Linkage methods using administrative claims data only primarily relied on family ID and estimated dates of maternal delivery and infant birth; proportions of mothers linked with infants were 56%–90%. Use of vital records, such as birth certificates, alongside claims data resulted in higher linkage proportions (> 86% of deliveries); examples were identified in Taiwan, Europe, and several US states. Utilization of birth records together with hospital discharge data resulted in linkages of over 90% of deliveries. Linkages involving additional data types, such as electronic health records, were identified in Europe and the US. Mother–infant linkages were straightforward in regions with national birth registers that include identifiers for mother and infant, such as the Nordic countries, and within integrated delivery networks in the US that provide both health insurance and care. Although most mother–infant linkages used deterministic methods, probabilistic methods typically achieved greater linkage proportions while requiring more data fields. Validations were uncommon; two studies demonstrated high positive predictive value (> 95%) but lower sensitivity (20%–88%).Discussion: Successful mother–infant data linkage occurs throughout the world and is enabled by aligned health care and technology infrastructure and policy. To increase trust in evidence generated from linked data, we encourage researchers and journals to include a description of linking methods, a quantification of linkage success, and, when possible, an assessment of linkage validity in peer‐reviewed publications.
- Top Cited PapersOpen Access
- 1 May 2025
- Published by American Society of Clinical Oncology (ASCO) in JCO Oncology Practice
- Vol. 21 (5) , 702-709
Real-World Safety and Health Care Resource Utilization of Teclistamab Under an Outpatient Model for Step-Up Dosing Administration
PURPOSE: Teclistamab is initiated with a step-up dosing (SUD) schedule to mitigate the risk of cytokine release syndrome (CRS) and immune effector cell–associated neurotoxicity syndrome (ICANS). Early teclistamab users commonly received SUD in a hospital setting. This study aimed to evaluate safety and health care resource utilization (HRU) in real-world patients with multiple myeloma who initiated teclistamab SUD in an outpatient setting. METHODS: This was a retrospective study using Mayo Clinic's electronic medical records from October 26, 2022, to October 31, 2023. Patient characteristics were summarized for all patients treated with teclistamab and separately for patients who started SUD outpatient. SUD pattern, safety, HRU, and post-SUD dosing schedule were described in patients with complete SUD. RESULTS: At data cutoff, 65 patients received ≥1 teclistamab dose, including 58 patients who initiated SUD outpatient (median age, 69.2 years; male, 63.8%; White, 89.7%). Among 57 patients who completed SUD in an outpatient setting, all received premedications on the days of teclistamab administrations per label recommendation; 18 (31.6%) developed CRS (13 grade 1, four grade 2, and one grade 4) and two developed ICANS (one each with grade 2 and 4). All CRS and ICANS resolved with supportive care and all patients continued treatment. Eighteen patients were admitted to the hospital for CRS treatment, with a median CRS-related hospital stay of 2 days per admission. Most (60%) doses during SUD required <1 hour clinic time between administration and checkout. Post-SUD, clinic time for treatment doses decreased to <30 minutes for most doses (82%). CONCLUSION: Outcomes of this study support outpatient administration as a safe and feasible option for teclistamab SUD to potentially reduce HRU and improve patient experiences.
- 1 May 2025
- Published by American Society of Clinical Oncology (ASCO) in JCO Oncology Practice
- Vol. 21 (5) , 702-709
Top Cited PapersOpen AccessReal-World Safety and Health Care Resource Utilization of Teclistamab Under an Outpatient Model for Step-Up Dosing Administration
PURPOSE: Teclistamab is initiated with a step-up dosing (SUD) schedule to mitigate the risk of cytokine release syndrome (CRS) and immune effector cell–associated neurotoxicity syndrome (ICANS). Early teclistamab users commonly received SUD in a hospital setting. This study aimed to evaluate safety and health care resource utilization (HRU) in real-world patients with multiple myeloma who initiated teclistamab SUD in an outpatient setting. METHODS: This was a retrospective study using Mayo Clinic's electronic medical records from October 26, 2022, to October 31, 2023. Patient characteristics were summarized for all patients treated with teclistamab and separately for patients who started SUD outpatient. SUD pattern, safety, HRU, and post-SUD dosing schedule were described in patients with complete SUD. RESULTS: At data cutoff, 65 patients received ≥1 teclistamab dose, including 58 patients who initiated SUD outpatient (median age, 69.2 years; male, 63.8%; White, 89.7%). Among 57 patients who completed SUD in an outpatient setting, all received premedications on the days of teclistamab administrations per label recommendation; 18 (31.6%) developed CRS (13 grade 1, four grade 2, and one grade 4) and two developed ICANS (one each with grade 2 and 4). All CRS and ICANS resolved with supportive care and all patients continued treatment. Eighteen patients were admitted to the hospital for CRS treatment, with a median CRS-related hospital stay of 2 days per admission. Most (60%) doses during SUD required <1 hour clinic time between administration and checkout. Post-SUD, clinic time for treatment doses decreased to <30 minutes for most doses (82%). CONCLUSION: Outcomes of this study support outpatient administration as a safe and feasible option for teclistamab SUD to potentially reduce HRU and improve patient experiences.
- Open Access
- 1 November 2024
- Published by Wiley in Pharmacology Research & Perspectives
- Vol. 12 (6) , e70024
Identification of cytokine release syndrome and indicators of severity in retrospective databases among patients receiving immunotherapy
Cytokine release syndrome (CRS) can occur following cancer immunotherapies, but is most often mild and of limited duration. International Classification of Diseases (ICD)‐10 codes allowing identification of CRS were introduced in 2020 but may be underutilized. We evaluated the performance of a published claims‐based algorithm to detect CRS (any grade) and high‐grade CRS (HG, grades 2‐5), as well as identified indicators of HG CRS in retrospective data. Adults with low‐grade and HG CRS during an encounter coinciding with administrations of blinatumomab or chimeric antigen receptor‐T therapy were identified in three types of retrospective databases (hospital chargemaster data, electronic health records, and administrative claims). The algorithm's sensitivity in detecting any CRS and HG CRS was reported. A least absolute shrinkage and selection operator (LASSO) regression model was developed to identify indicators of HG CRS. Performance of the model was evaluated using area under the curve (AUC). The sensitivity of the algorithm to detect any grade CRS ranged between 77%–100% and between 8%–80% for HG CRS, depending on the type of database. The LASSO model identified hypotension, positive pressure (including mechanical ventilation), tocilizumab, and vasopressors as indicators of HG CRS. AUC varied between 60% and 75%. The algorithm accurately detected any grade CRS for over three‐quarters of instances, but was not as reliable for HG CRS. Results varied based on database attributes. Hypotension, vasopressors, positive pressure, and tocilizumab were associated with HG CRS and may be methodologically helpful signals of CRS severity in retrospective data.
- 1 November 2024
- Published by Wiley in Pharmacology Research & Perspectives
- Vol. 12 (6) , e70024
Open AccessIdentification of cytokine release syndrome and indicators of severity in retrospective databases among patients receiving immunotherapy
Cytokine release syndrome (CRS) can occur following cancer immunotherapies, but is most often mild and of limited duration. International Classification of Diseases (ICD)‐10 codes allowing identification of CRS were introduced in 2020 but may be underutilized. We evaluated the performance of a published claims‐based algorithm to detect CRS (any grade) and high‐grade CRS (HG, grades 2‐5), as well as identified indicators of HG CRS in retrospective data. Adults with low‐grade and HG CRS during an encounter coinciding with administrations of blinatumomab or chimeric antigen receptor‐T therapy were identified in three types of retrospective databases (hospital chargemaster data, electronic health records, and administrative claims). The algorithm's sensitivity in detecting any CRS and HG CRS was reported. A least absolute shrinkage and selection operator (LASSO) regression model was developed to identify indicators of HG CRS. Performance of the model was evaluated using area under the curve (AUC). The sensitivity of the algorithm to detect any grade CRS ranged between 77%–100% and between 8%–80% for HG CRS, depending on the type of database. The LASSO model identified hypotension, positive pressure (including mechanical ventilation), tocilizumab, and vasopressors as indicators of HG CRS. AUC varied between 60% and 75%. The algorithm accurately detected any grade CRS for over three‐quarters of instances, but was not as reliable for HG CRS. Results varied based on database attributes. Hypotension, vasopressors, positive pressure, and tocilizumab were associated with HG CRS and may be methodologically helpful signals of CRS severity in retrospective data.
- Open Access
- 13 November 2019
- Published by American Society of Hematology in Blood
- Vol. 134 (Supplement) , 5517
Diagnostic Delay and Characterization of the Clinical Prodrome in AL Amyloidosis: Data from 1,313 US Commercially Insured Patients between 2006-2018
Introduction:Light chain (AL) amyloidosis is a rare clonal plasma cell disorder characterized by the organ deposition of amyloid derived from misfolded immunoglobulin light chains. The involvement of vital organs, especially the heart, results in severe morbidity and high early mortality. Diagnostic delays of greater than 1 year from clinical evidence of AL have been reported in surveys and retrospective single-center studies. Earlier diagnosis prior to developing advanced organ dysfunction is a key unmet need in AL. To detect patients earlier, a better understanding of the patterns of AL-related signs/symptoms (AL-S/Sx) and healthcare utilization preceding AL amyloidosis diagnosis is necessary. Methods: Using the Optum De-Identified Clinformatics® Data Mart healthcare claims database (Optum), we identified US commercially-insured patients who had one inpatient code or two outpatient codes of ICD-9-CM 277.30 or ICD-10-CM E85.81, E85.89, or E85.9 and treatment with one multiple myeloma drug within 90 days of diagnosis (01Jan06-31Dec18). Twenty-three AL-S/Sx were defined with sets of diagnosis codes, flagged in prior condition lists, and grouped by system affected (cardiac, nervous, renal/ureter, gastrointestinal, or other). The time between the first occurrence of each symptom and AL diagnosis was summarized and healthcare utilization patterns were described to better characterize the patient journey to diagnosis. Results: Among 1313 AL patients, the median time from the first potential AL-S/Sx to AL diagnosis was 2.5 years. The most common AL-S/Sx were malaise/fatigue (53%), edema and swelling (57%), dyspnea (53%), and abdominal pain (52%), which occurred a median of 1-1.8 years prior to diagnosis. Arrhythmia (51%), cardiomegaly (27%), and cardiomyopathy (21%) were identifiable between a median of 1-1.5 years before diagnosis. Chronic kidney disease (45%) and edema (57%) were seen a median of 2.3 years prior to diagnosis. Patients with a first symptom of nephrotic syndrome presented less than 1 year before diagnosis. Peripheral nerve disease (46%), neuralgias (14%), and paresthesia/anesthesia (20%) appeared a median of 2.8 years prior to diagnosis. The cumulative incidence of each AL-S/Sx by organ system in the 5 years prior to diagnosis is shown in Figure 1. Sequencing of symptoms varied greatly among patients. The most common first symptoms in the sequences were abdominal pain, malaise/fatigue/weakness, peripheral nerve disease, and arrhythmia. Between initial AL-S/Sx and diagnosis, 20% of patients had 3 or more ER visits and 16% had 3 or more hospitalizations. More than 90% of patients visited 5 or more provider types between the first AL-S/Sx and AL diagnosis, with the most frequent specialties visited being cardiology (67%), hematology/oncology (43%), and gastroenterology (40%). About one quarter of patients had a monoclonal gammopathy detected at a median of 1 year prior to diagnosis; detailed analyses of this cohort will be presented at the meeting. Conclusion: AL patients have a prolonged prodrome, including evidence of cardiac and renal dysfunction, with 50% of patients with a first AL-S/Sx observed more than 2.5 years before AL diagnosis. Only one-quarter of patients had a monoclonal protein detected before diagnosis, indicating a low level of suspicion for AL. Limitations of this study include underestimation of AL S/Sx if diagnosis codes are underutilized in claims. Future studies will use controls to understand background rates of symptoms. Overall, these findings suggest that novel approaches to early diagnosis have significant potential to improve outcomes in AL. Figure 1.Cumulative incidence of the first occurrence of potential symptoms prior to the first light chain (AL) amyloidosis diagnosis
- 13 November 2019
- Published by American Society of Hematology in Blood
- Vol. 134 (Supplement) , 5517
Open AccessDiagnostic Delay and Characterization of the Clinical Prodrome in AL Amyloidosis: Data from 1,313 US Commercially Insured Patients between 2006-2018
Introduction:Light chain (AL) amyloidosis is a rare clonal plasma cell disorder characterized by the organ deposition of amyloid derived from misfolded immunoglobulin light chains. The involvement of vital organs, especially the heart, results in severe morbidity and high early mortality. Diagnostic delays of greater than 1 year from clinical evidence of AL have been reported in surveys and retrospective single-center studies. Earlier diagnosis prior to developing advanced organ dysfunction is a key unmet need in AL. To detect patients earlier, a better understanding of the patterns of AL-related signs/symptoms (AL-S/Sx) and healthcare utilization preceding AL amyloidosis diagnosis is necessary. Methods: Using the Optum De-Identified Clinformatics® Data Mart healthcare claims database (Optum), we identified US commercially-insured patients who had one inpatient code or two outpatient codes of ICD-9-CM 277.30 or ICD-10-CM E85.81, E85.89, or E85.9 and treatment with one multiple myeloma drug within 90 days of diagnosis (01Jan06-31Dec18). Twenty-three AL-S/Sx were defined with sets of diagnosis codes, flagged in prior condition lists, and grouped by system affected (cardiac, nervous, renal/ureter, gastrointestinal, or other). The time between the first occurrence of each symptom and AL diagnosis was summarized and healthcare utilization patterns were described to better characterize the patient journey to diagnosis. Results: Among 1313 AL patients, the median time from the first potential AL-S/Sx to AL diagnosis was 2.5 years. The most common AL-S/Sx were malaise/fatigue (53%), edema and swelling (57%), dyspnea (53%), and abdominal pain (52%), which occurred a median of 1-1.8 years prior to diagnosis. Arrhythmia (51%), cardiomegaly (27%), and cardiomyopathy (21%) were identifiable between a median of 1-1.5 years before diagnosis. Chronic kidney disease (45%) and edema (57%) were seen a median of 2.3 years prior to diagnosis. Patients with a first symptom of nephrotic syndrome presented less than 1 year before diagnosis. Peripheral nerve disease (46%), neuralgias (14%), and paresthesia/anesthesia (20%) appeared a median of 2.8 years prior to diagnosis. The cumulative incidence of each AL-S/Sx by organ system in the 5 years prior to diagnosis is shown in Figure 1. Sequencing of symptoms varied greatly among patients. The most common first symptoms in the sequences were abdominal pain, malaise/fatigue/weakness, peripheral nerve disease, and arrhythmia. Between initial AL-S/Sx and diagnosis, 20% of patients had 3 or more ER visits and 16% had 3 or more hospitalizations. More than 90% of patients visited 5 or more provider types between the first AL-S/Sx and AL diagnosis, with the most frequent specialties visited being cardiology (67%), hematology/oncology (43%), and gastroenterology (40%). About one quarter of patients had a monoclonal gammopathy detected at a median of 1 year prior to diagnosis; detailed analyses of this cohort will be presented at the meeting. Conclusion: AL patients have a prolonged prodrome, including evidence of cardiac and renal dysfunction, with 50% of patients with a first AL-S/Sx observed more than 2.5 years before AL diagnosis. Only one-quarter of patients had a monoclonal protein detected before diagnosis, indicating a low level of suspicion for AL. Limitations of this study include underestimation of AL S/Sx if diagnosis codes are underutilized in claims. Future studies will use controls to understand background rates of symptoms. Overall, these findings suggest that novel approaches to early diagnosis have significant potential to improve outcomes in AL. Figure 1.Cumulative incidence of the first occurrence of potential symptoms prior to the first light chain (AL) amyloidosis diagnosis
- Open Access
- 1 December 2007
- Published by Elsevier in The American Journal of Clinical Nutrition
- Vol. 86 (6) , 1730-1737
Association between dietary fiber and endometrial cancer: a dose-response meta-analysis
Background: Endometrial cancer is the most common female gynecologic cancer in the United States. Excessive and prolonged exposure of the endometrium to estrogens unopposed by progesterone and a high body mass are well-established risk factors for endometrial cancer. Although dietary fiber has been shown to beneficially reduce estrogen concentrations and prevent obesity, its role in endometrial cancer has received relatively little attention. Objective: The objective was to summarize and quantify the current evidence of a role of dietary fiber consumption in endometrial cancer risk and to identify research gaps in this field. Design: We conducted a systematic literature review of articles published through February 2007 to summarize the current evidence of a relation between dietary fiber consumption and endometrial cancer risk and to quantify the magnitude of the association by conducting a dose-response meta-analysis. Results: Ten articles representing 1 case-cohort study and 9 case-control studies that evaluated several aspects of fiber consumption and endometrial cancer risk were identified through searches in various databases. On the basis of 7 case-control studies, the random-effects summary risk estimate was 0.82 (95% CI: 0.75, 0.90) per 5 g/1000 kcal dietary fiber, with no evidence of heterogeneity (I2: 0%, P for heterogeneity: 0.55). The random-effects summary estimate was 0.71 (95% CI: 0.59, 0.85) for the comparison of the highest with the lowest dietary fiber intake in 8 case-control studies, with little evidence of heterogeneity (I2: 20.8%, P for heterogeneity: 0.26). In contrast, the only prospective study that evaluated this association did not find an association. Conclusions: Although the current evidence, based on data from case-control studies, supports an inverse association between dietary fiber and endometrial cancer, additional population-based studies, particularly cohort studies, are needed before definitive conclusions can be drawn.
- 1 December 2007
- Published by Elsevier in The American Journal of Clinical Nutrition
- Vol. 86 (6) , 1730-1737
Open AccessAssociation between dietary fiber and endometrial cancer: a dose-response meta-analysis
Background: Endometrial cancer is the most common female gynecologic cancer in the United States. Excessive and prolonged exposure of the endometrium to estrogens unopposed by progesterone and a high body mass are well-established risk factors for endometrial cancer. Although dietary fiber has been shown to beneficially reduce estrogen concentrations and prevent obesity, its role in endometrial cancer has received relatively little attention. Objective: The objective was to summarize and quantify the current evidence of a role of dietary fiber consumption in endometrial cancer risk and to identify research gaps in this field. Design: We conducted a systematic literature review of articles published through February 2007 to summarize the current evidence of a relation between dietary fiber consumption and endometrial cancer risk and to quantify the magnitude of the association by conducting a dose-response meta-analysis. Results: Ten articles representing 1 case-cohort study and 9 case-control studies that evaluated several aspects of fiber consumption and endometrial cancer risk were identified through searches in various databases. On the basis of 7 case-control studies, the random-effects summary risk estimate was 0.82 (95% CI: 0.75, 0.90) per 5 g/1000 kcal dietary fiber, with no evidence of heterogeneity (I2: 0%, P for heterogeneity: 0.55). The random-effects summary estimate was 0.71 (95% CI: 0.59, 0.85) for the comparison of the highest with the lowest dietary fiber intake in 8 case-control studies, with little evidence of heterogeneity (I2: 20.8%, P for heterogeneity: 0.26). In contrast, the only prospective study that evaluated this association did not find an association. Conclusions: Although the current evidence, based on data from case-control studies, supports an inverse association between dietary fiber and endometrial cancer, additional population-based studies, particularly cohort studies, are needed before definitive conclusions can be drawn.